{
    "clinical_study": {
        "@rank": "157924", 
        "arm_group": [
            {
                "arm_group_label": "Zoladex combined with chemotherapy", 
                "arm_group_type": "Experimental", 
                "description": "After signing informed consent, patients will be screened, eligible patients were randomly divided into 2 groups, the test group should use Zoladex 3.6mg once a month up to 2-3 years combined with chemotherapy,all patients will receive Tamoxifen after chemotherapy"
            }, 
            {
                "arm_group_label": "Zoladex after chemotherapy", 
                "arm_group_type": "Active Comparator", 
                "description": "After signing informed consent, patients will be screened, eligible patients were randomly divided into 2 groups, the control group should use Zoladex 3.6mg once a month up to 2-3 years after chemotherapy,all patients will receive Tamoxifen after chemotherapy"
            }
        ], 
        "brief_summary": {
            "textblock": "The present study is a randomized open-label -phase III study that aims to compare the\n      efficacy and safety of the adjuvant chemotherapy with simultaneous or sequential application\n      of Zoladex up to 2-3 years for \u2264 45 year old premenopausal hormone receptor-positive breast\n      cancer."
        }, 
        "brief_title": "Simultaneous Versus Sequential Use of Adjuvant Chemotherapy and GnRHa in Treating ER+,Premenopausal Breast Cancer", 
        "completion_date": {
            "#text": "September 2018", 
            "@type": "Anticipated"
        }, 
        "condition": "Breast Cancer", 
        "condition_browse": {
            "mesh_term": "Breast Neoplasms"
        }, 
        "detailed_description": {
            "textblock": "Data showed that ovarian suppression therapy may protect the ovarian function in\n      premenopausal patients received chemotherapy for breast cancer. However this is still a\n      controversial issue. Sequential use of GnRHa (Zoladex) as ovarian suppression treatment\n      after chemotherapy has been established as an effective endocrine therapy for ER positive\n      premenopausal breast cancer. The present study is a randomized open-label phase III study\n      that aims to observe the efficacy and safety of the adjuvant chemotherapy with simultaneous\n      combination of Zoladex up to 2-3years and chemotherapy compared with the sequential schedule\n      in \u2264 45 year old premenopausal hormone receptor-positive breast cancer patients."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          1. female\n\n          2. Primary invasive breast cancer pathologically approved by core needle or open biopsy\n\n          3. Patients must have undergone standard surgery for primary breast cancer as shown in\n             the following:\n\n               -  mastectomy\n\n               -  breast conservation surgery followed by whole breast radiation\n\n               -  axillary dissection or sentinel node biopsy\n\n          4. Need adjuvant chemotherapy after surgery\n\n          5. Patients taking neo-chemotherapy are eligible\n\n          6. Patients with synchronous bilateral cancers are eligible on the condition that If one\n             side is IDC and the other side is DCIS, the IDC side should be of the ER and/or PR\n             positive phenotype and IF two sides are both IDC, they must be ER and/or PR positive\n             phenotype at the same time\n\n          7. Hormone receptor positive (\u2265\uff0b) is defined as detecting ER or PR expression at any\n             time is eligible. The situation of only PR positive and ER negative is eligible, too\n\n          8. Based on the study objective, all patients are required to be premenopausal as\n             defined by\n\n               -  menstruating actively\n\n               -  less than 6 months since last menstrual period (LMP), or patients younger than\n                  40 years of age who became amenorrheic not more than 1 year if the serum free\n                  E2\u3001FSH and LH level was premenopausal (according to the reference value of local\n                  center).\n\n               -  had previous hysterectomy with one or both ovaries left intact are eligible if\n                  the serum free E2\u3001FSH and LH level are premenopausal (according to the reference\n                  value of local center).\n\n          9. patients must have an ECOG performance status of 0 or 1 (0-fully active, able to\n             carry on all pre-disease performance without restriction, 1-restricted in physical\n             strenuous actively but ambulatory)\n\n         10. leucocyte count must be \u2265 3.0*10^9/L and platelet count must be \u2265 100*10^9/L\n\n         11. AST/SGOT or ALT/AGPT must be < 3 times the ULN\n\n         12. serum creatinine must be < 2 times the ULN\n\n         13. pregnancy testing is negative and are willing to do contraception during the\n             treatment period\n\n        Exclusion Criteria:\n\n          1. patients with metastatic malignant tumor\n\n          2. previous history of asynchronous bilateral breast cancer\n\n          3. any previous malignancy in the past 5 years, except for those treated with curative\n             intent, such as carcinoma in situ of the cervix, squamous carcinoma of the skin or\n             basal cell carcinoma of the skin\n\n          4. any non-malignant systemic disease which interfere long time follow up\n\n          5. history of medical ovarian ablation therapy\n\n          6. severe live dysfunction, Child\uff0dPugh is grade C\n\n          7. Severe renal dysfunction\n\n          8. Occult breast cancer\n\n          9. severe heart dysfunction, heart functional classification is above Class III"
            }, 
            "gender": "Female", 
            "healthy_volunteers": "No", 
            "maximum_age": "45 Years", 
            "minimum_age": "N/A"
        }, 
        "enrollment": {
            "#text": "220", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "October 21, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01712893", 
            "org_study_id": "CD trial"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "Zoladex combined with chemotherapy", 
                    "Zoladex after chemotherapy"
                ], 
                "description": "Eligible patients were randomly divided into 2 groups, the intervention group should use Zoladex 3.6mg once a month up to 2-3 years combined with chemotherapy,and the control group should use chemotherapy alone followed by Zoladex", 
                "intervention_name": "Zoladex", 
                "intervention_type": "Drug", 
                "other_name": "Zoladex = GnRHa,Goserelin"
            }, 
            {
                "arm_group_label": [
                    "Zoladex combined with chemotherapy", 
                    "Zoladex after chemotherapy"
                ], 
                "description": "After signing informed consent, patients will be screened, eligible patients were randomly divided into 2 groups, the control group should Switch to use Zoladex 3.6mg once a month after chemotherapy up to 2-3 years,all patients will receive Tamoxifen after chemotherapy", 
                "intervention_name": "chemotherapy (Anthrocyclin combined with or followed by Taxanes)", 
                "intervention_type": "Drug", 
                "other_name": "Anthrocyclin combined with or followed by Taxanes"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Goserelin", 
                "Taxane"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "breast cancer", 
            "adjuvant therapy", 
            "Ovarian suppression"
        ], 
        "lastchanged_date": "October 23, 2012", 
        "location": {
            "contact": {
                "email": "liugy123@yahoo.com", 
                "last_name": "guang-yu Liu, MD", 
                "phone": "86-021-64175590", 
                "phone_ext": "8808"
            }, 
            "facility": {
                "address": {
                    "city": "Shanghai", 
                    "country": "China", 
                    "state": "Shanghai", 
                    "zip": "200032"
                }, 
                "name": "FUSCC"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "China"
        }, 
        "number_of_arms": "2", 
        "official_title": "A Phase III,Randomized,Open Label Study Comparing Simultaneous Versus Sequential Use of Adjuvant Chemotherapy and GnRHa up to 2-3 Years for \u2264 45 Year Old Pre-menopausal Hormone Receptor-positive Breast Cancer", 
        "overall_contact": {
            "email": "zhimingshao@yahoo.com", 
            "last_name": "Zhi-Min Shao, MD", 
            "phone": "86-021-64175590 ext 8808", 
            "phone_ext": "8808"
        }, 
        "overall_contact_backup": {
            "email": "liugy123@yahoo.com", 
            "last_name": "Guang-Yu Liu, MD", 
            "phone": "86-021-64175590 ext 8808"
        }, 
        "overall_official": {
            "affiliation": "Fudan University", 
            "last_name": "Zhi-Min Shao, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "China: Food and Drug Administration", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "September 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "the Resumption that patients recover the natural menstrual or serum E2, FSH, LH return to the premenopausal range within 1 year after stopping Zoladex", 
            "measure": "Resumption of menstruation", 
            "safety_issue": "No", 
            "time_frame": "1 year"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01712893"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Fudan University", 
            "investigator_full_name": "Zhimin Shao", 
            "investigator_title": "Director of Department of Surgical Oncology,Cancer Hospital & Institute", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": [
            {
                "description": "Relapse free survival (RFS): RFS related events ware defined as local-regional recurrence, distant metastasis or death, whichever occurred first.during follow up", 
                "measure": "RFS", 
                "safety_issue": "No", 
                "time_frame": "5years"
            }, 
            {
                "description": "Overall survival", 
                "measure": "OS", 
                "safety_issue": "No", 
                "time_frame": "5 years"
            }, 
            {
                "description": "Other adverse events (Gynecological events, blood lipids, thrombosis, cardiovascular diseases, and etc.)", 
                "measure": "Other adverse events", 
                "safety_issue": "Yes", 
                "time_frame": "5years"
            }
        ], 
        "source": "Fudan University", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Fudan University", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "June 2009", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "October 2012"
    }
}